ReviewStem cell reviews and reports2017
High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.
Review in Stem cell reviews and reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Planar-electroporated cell biosensor for investigating potential therapeutic effects of ectopic bitter receptors.Microsystems & nanoengineering · 2025Article
- Dressed in Collagen: 2D and 3D Cardiac Fibrosis Models.International journal of molecular sciences · 2025Review
- Optical Image Sensors for Smart Analytical Chemiluminescence Biosensors.Bioengineering (Basel, Switzerland) · 2024Review
- Strategies to reduce the risks of mRNA drug and vaccine toxicity.Nature reviews. Drug discovery · 2024Review
- Construction of cardiac fibrosis for biomedical research.Smart medicine · 2023Review
- Dynamic mechanobiology of cardiac cells and tissues: Current status and future perspective.Biophysics reviews · 2023Review
- iPSC-Derived Cardiomyocytes in Inherited Cardiac Arrhythmias: Pathomechanistic Discovery and Drug Development.Biomedicines · 2023Review
- Article
- Biomimetic design of bioartificial scaffolds for theFrontiers in bioengineering and biotechnology · 2022Article
- Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases.Cardiovascular research · 2021Review
- Liver-Heart on chip models for drug safety.APL bioengineering · 2021Review
- Microphysiological systems: What it takes for community adoption.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Microfluidic platform accelerates tissue processing into single cells for molecular analysis and primary culture models.Nature communications · 2021Article
- Microfluidic integration of regeneratable electrochemical affinity-based biosensors for continual monitoring of organ-on-a-chip devices.Nature protocols · 2021Article
- 3D bioprinting in cardiac tissue engineering.Theranostics · 2021Review
- Rapid Makerspace Microfabrication and Characterization of 3D Microelectrode Arrays (3D MEAs) for Organ-on-a-Chip Models.Journal of microelectromechanical systems : a joint IEEE and ASME publication on microstructures, microactuators, microsensors, and microsystems · 2021Article
- Cardiac tissue engineering therapeutic products to enhance myocardial contractility.Journal of muscle research and cell motility · 2020Review
- Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review.Micromachines · 2020Review
- Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.Advanced healthcare materials · 2020Review
- Microphysiological Systems: Next Generation Systems for Assessing Toxicity and Therapeutic Effects of Nanomaterials.Small methods · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Drug discovery and development continues to be a challenge to the pharmaceutical industry despite great advances in cell and molecular biology that allow for the design of better targeted therapeutics. Many potential drug compounds fail during the clinical trial due to inefficacy and toxicity that were not predicted during preclinical stages. The fundamental problem lies with the use of traditional drug screening models that still largely rely on the use of cell lines or animal cell monolayers, which leads to lack of predictive power of human tissue and organ response to the drug candidates. More physiologically relevant systems are therefore critical in relieving the burden of high failure rates. Emerging knowledge and techniques in tissue engineering and microfabrication have enabled the development of micro-engineered systems - collectively known as organs-on-chips - that may lead to a paradigm shift in preclinical drug screening assays. In this review we explore the technological advances and challenges in the development of heart-on-a-chip models, by addressing current assessment methods for drug-induced cardiotoxicity and providing a perspective on the modifications that should be implemented to realize the full potential of this system.
Indexed as
Identifiers
28429185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.